Status:
COMPLETED
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
Lead Sponsor:
Mesoblast, Inc.
Conditions:
Graft Versus Host Disease
Eligibility:
All Genders
6-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and gather additional safety information for Prochymal® in participants who have failed to respond to steroid treatment of Grades B-D acute GVHD.
Detailed Description
Approximately 6300 patients receive allogeneic hematopoietic stem cell transplants in the United States each year (International Bone Marrow Transplant Registry \[IBMTR\], 2003). Nearly 50% (approxima...
Eligibility Criteria
Inclusion
- Participant must be 6 months to 70 years of age, inclusive.
- Participants who have failed to respond to steroid treatment.
- Failure to respond to steroid treatment is defined as any grade B-D (IBMTR) grading of acute GVHD that shows:
- No improvement after 3 days and a duration of no greater than 2 weeks while receiving treatment with methylprednisolone (greater than or equal to 1 mg/kg/day) or equivalent.
- Participant must be treated within 4 days of randomization. In urgent situations 2nd line therapy may be started 24 hours prior to randomization, and Prochymal® must be initiated within the following 3 days.
- Participants who have received an increase in their steroid dose treatment prior to randomization will be eligible for enrollment. An increase in steroid dose will not be considered as second line therapy.
- Participant must have adequate renal function as defined by: Calculated Creatinine Clearance of \>30 milliliters per minute (mL/min) using the Cockcroft-Gault equation.
- For pediatric participants: Schwartz equation: (Participant population: infants over 1 week old through adolescence (\<18 years old).
- Participants who are women of childbearing potential must be non-pregnant, not breast-feeding, and use adequate contraception. Male participants must use adequate contraception.
- Participant must have a minimum Karnofsky Performance Level of at least 30 at the time of study entry.
- Participant (or legal representative where appropriate) must be capable of providing written informed consent.
Exclusion
- Participant has started treatment with second line therapy \>24 hours prior to randomization.
- Participant has received agents other than steroids for primary treatment of acute GVHD.
- Participant is participating in the CTN Protocol 0302.
- Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant including uncontrolled infection, heart failure, pulmonary hypertension, etc.
- Participant may not receive any other investigational agents (not approved by the FDA) concurrently during study participation or within 30 days of randomization.
- Participant has a known allergy to bovine or porcine products.
- Participant has received a transplant for a solid tumor disease.
Key Trial Info
Start Date :
August 17 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2009
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00366145
Start Date
August 17 2006
End Date
May 28 2009
Last Update
February 10 2022
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35249
2
Arizona Cancer Center
Tucson, Arizona, United States, 85724
3
City of Hope
Duarte, California, United States, 91010
4
Univeristy of California San Francisco
San Francisco, California, United States, 94143